Evidence map›Paper›PMID 41907408›Full record

ArticleiScience2026

AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis.

Guang-Shun Sun, Yi-Han Li, Li Li, Li-Li Fan, Hui Yang, Qun Lu, Zhao Liu, Shui Wang, Jin-Juan Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guang-Shun SunDepartment of Breast Surgery, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yi-Han LiDepartment of Breast Surgery, The First Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Li LiDepartment of Breast Surgery, The Fourth People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China.
Li-Li FanDepartment of Breast Surgery, The Fourth People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China.
Hui YangDepartment of Breast Surgery, The Fourth People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China.
Qun LuDepartment of Breast Surgery, Changzhou Maternity and Child Health Care Hospital, Changzhou, Jiangsu, China.
Zhao LiuDepartment of Thyroid and Breast Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Shui WangDepartment of Breast Surgery, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jin-Juan PengDepartment of Breast Surgery, The First Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenylate kinase 5 (AK5) is a poorly characterized metabolic enzyme with unknown roles in breast cancer. Single-cell transcriptomics revealed AK5 enrichment in malignant epithelial cells, and its low expression correlated with poor patient prognosis, suggesting tumor-suppressive functions. Functionally, AK5 overexpression inhibited, while its knockdown promoted, breast cancer cell proliferation, migration, and invasion. Mechanistically, AK5, dependent on its kinase activity, post-transcriptionally suppressed miR-182-5p maturation, thereby de-repressing -L1 expression.

Indexed as

CancerImmune responseTherapy

Identifiers

PMID41907408
PMCPMC13018875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.